Ultra-short acting beta-blockers: a proposal for the treatment of the critically ill patient.
Beta-blockade is of proven value in the therapy of acute myocardial infarction but, unfortunately, may produce cardiac failure by removal of needed sympathetic support. The long duration of action of available blockers (hours) makes reversal of failure a complicated problem and precludes rapid modification of therapy to match changing autonomic conditions. To improve the safety and efficacy of beta-blockade in this setting we have developed the concept of ultra-short beta-blockade and have identified a novel beta-blocker (ASL-8052) which possesses a duration of action less than 15 minutes. This compound is cardioselective and possesses efficacy in an animal model of acute myocardial infarction. It, therefore, appears to be suitable for rapid attainment of controlled levels of beta-blockade via intravenous infusion and rapid recovery from beta-blockade if required by the clinical situation. The compound should, therefore, be useful for safe therapy in critically ill cardiac patients.
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D006168:Guinea Pigs; D006331:Heart Diseases / Q000139:chemically induced; D066298:In Vitro Techniques; D009203:Myocardial Infarction / Q000188:drug therapy*; D011412:Propanolamines / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; C036604:esmolol